Keywords: doxorubicin, transdrug, performs, well, liver, cancer, study

Doxorubicin Transdrug performs well in liver cancer study

Article | 10 July 2006

Print This

French specialty pharmaceutical company BioAlliance Pharma says that it has achieved promising results from a Phase I/II study of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in